Oncoinvent ASA Statistics

Total Valuation

Oncoinvent ASA has a market cap or net worth of NOK 180.83 million. The enterprise value is 54.61 million.

Market Cap	180.83M
Enterprise Value	54.61M

Important Dates

The next estimated earnings date is Wednesday, August 27, 2025.

Earnings Date	Aug 27, 2025
Ex-Dividend Date	n/a

Share Statistics

Oncoinvent ASA has 97.74 million shares outstanding.

Current Share Class	97.74M
Shares Outstanding	97.74M
Shares Change (YoY)	n/a
Shares Change (QoQ)	+381.57%
Owned by Insiders (%)	11.80%
Owned by Institutions (%)	21.15%
Float	51.09M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	22.32
PB Ratio	1.67
P/TBV Ratio	1.67
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-0.39
EV / Sales	6.74
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-0.61

Financial Position

The company has a current ratio of 2.49, with a Debt / Equity ratio of 0.07.

Current Ratio	2.49
Quick Ratio	2.41
Debt / Equity	0.07
Debt / EBITDA	n/a
Debt / FCF	-0.08
Interest Coverage	-1,762.71

Financial Efficiency

Return on equity (ROE) is -171.75% and return on invested capital (ROIC) is -96.38%.

Return on Equity (ROE)	-171.75%
Return on Assets (ROA)	-65.35%
Return on Invested Capital (ROIC)	-96.38%
Return on Capital Employed (ROCE)	-124.71%
Revenue Per Employee	238,324
Profits Per Employee	-4.12M
Employee Count	34
Asset Turnover	0.06
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	1.86
200-Day Moving Average	n/a
Relative Strength Index (RSI)	47.26
Average Volume (20 Days)	49,333

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Oncoinvent ASA had revenue of NOK 8.10 million and -140.20 million in losses. Loss per share was -1.52.

Revenue	8.10M
Gross Profit	8.10M
Operating Income	-141.02M
Pretax Income	-140.20M
Net Income	-140.20M
EBITDA	-131.81M
EBIT	-141.02M
Loss Per Share	-1.52

Full Income Statement

Balance Sheet

The company has 133.67 million in cash and 7.45 million in debt, giving a net cash position of 126.22 million or 1.29 per share.

Cash & Cash Equivalents	133.67M
Total Debt	7.45M
Net Cash	126.22M
Net Cash Per Share	1.29
Equity (Book Value)	108.33M
Book Value Per Share	1.17
Working Capital	86.36M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -87.94 million and capital expenditures -1.80 million, giving a free cash flow of -89.75 million.

Operating Cash Flow	-87.94M
Capital Expenditures	-1.80M
Free Cash Flow	-89.75M
FCF Per Share	-0.92

Full Cash Flow Statement

Margins

Gross Margin	100.00%
Operating Margin	-1,740.31%
Pretax Margin	-1,730.24%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Oncoinvent ASA does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-77.53%
FCF Yield	-49.63%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Oncoinvent ASA has an Altman Z-Score of -4.53. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-4.53
Piotroski F-Score	n/a